Entia Biosciences, Inc. (OTCQB: ERGO) Enters into Exclusive Worldwide Licensing Agreement for its GROH Beauty Products Line
24. Februar 2017 16:01 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) announced that it has licensed to GROH BEAUTY CORP of Deerfield Beach, Florida, the exclusive worldwide rights...
Entia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic Uses
02. November 2016 15:20 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title...
Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting
06. Oktober 2016 12:52 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical...
Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
26. September 2016 08:30 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected...
UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
21. Dezember 2015 15:12 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...
Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
21. Dezember 2015 08:50 ET
|
Entia Biosciences, Inc.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...
Entia Biosciences Launches Medical Food for Treatment of Rheumatoid Arthritis
02. Mai 2012 09:20 ET
|
Entia Biosciences, Inc.
SHERWOOD, Ore., May 2, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) has developed a new medical food for the treatment of Rheumatoid Arthritis (RA), a systemic autoimmune...
Entia Biosciences Developing ErgoD2(TM) Line of Medical Foods
24. Februar 2012 14:27 ET
|
Entia Biosciences, Inc.
SHERWOOD, Ore., Feb. 24, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGOD) (ENTIA) announced today that it is developing a line of medical food products based on its proprietary...
ErgoD2 Achieves Important Safety Milestone for Entia Biosciences
01. Februar 2012 09:30 ET
|
Entia Biosciences, Inc.
SHERWOOD, Ore., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) announced today that it has successfully completed an acute oral toxicity study (LD50) with its...
Dr. Paul Vanhoutte to Serve as Co-chairman of Entia's Scientific Advisory Board
11. Januar 2012 09:30 ET
|
Entia Biosciences, Inc.
SHERWOOD, Ore., Jan. 11, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) announced today that Dr. Paul M. Vanhoutte MD, Ph.D., the internationally respected cardiologist and...